

REVIEW

Open Access



Temperature control after cardiac arrest

Claudio Sandroni^{1,2,5*}, Daniele Natalini² and Jerry P. Nolan^{3,4}

Abstract

Most of the patients who die after cardiac arrest do so because of hypoxic-ischemic brain injury (HIBI). Experimental evidence shows that temperature control targeted at hypothermia mitigates HIBI. In 2002, one randomized trial and one quasi-randomized trial showed that temperature control targeted at 32–34 °C improved neurological outcome and mortality in patients who are comatose after cardiac arrest. However, following the publication of these trials, other studies have questioned the neuroprotective effects of hypothermia. In 2021, the largest study conducted so far on temperature control (the TTM-2 trial) including 1900 adults comatose after resuscitation showed no effect of temperature control targeted at 33 °C compared with normothermia or fever control. A systematic review of 32 trials published between 2001 and 2021 concluded that temperature control with a target of 32–34 °C compared with fever prevention did not result in an improvement in survival (RR 1.08; 95% CI 0.89–1.30) or favorable functional outcome (RR 1.21; 95% CI 0.91–1.61) at 90–180 days after resuscitation. There was substantial heterogeneity across the trials, and the certainty of the evidence was low. Based on these results, the International Liaison Committee on Resuscitation currently recommends monitoring core temperature and actively preventing fever (37.7 °C) for at least 72 h in patients who are comatose after resuscitation from cardiac arrest. Future studies are needed to identify potential patient subgroups who may benefit from temperature control aimed at hypothermia. There are no trials comparing normothermia or fever control with no temperature control after cardiac arrest.

Keywords: Cardiac arrest, Coma, Hypothermia, Hypoxic-ischemic brain injury, Temperature control

Background

Cardiac arrest ranks among the most important causes of mortality worldwide. In the USA, almost 90 individuals per 100,000 population are resuscitated from out-of-hospital cardiac arrest (OHCA) [1]. The incidence of in-hospital cardiac arrest (IHCA) has been estimated to be between 0.6 and 5 events per 1000 patient admissions [2, 3]. More than two-thirds of patients resuscitated from OHCA [4], and about one-quarter of those resuscitated from IHCA [5] die of hypoxic-ischemic brain injury (HIBI) [6]. Temperature control has been the most widely studied among the strategies for reducing the severity of HIBI. The present review summarizes the experimental

and clinical evidence, the most recent recommendations, and future research directions regarding the use of temperature control after cardiac arrest.

Pathophysiology and rationale

The human brain is very susceptible to HIBI—consciousness is lost between 4 and 10 s after the arrest of cerebral blood flow and the electroencephalogram becomes isoelectric 10–30 s after circulatory arrest. Irreversible damage to the neurons starts immediately upon cessation of cerebral perfusion because of the lack of inherent energy stores, and it continues after reperfusion due to the release of excitatory amino acids, intracellular calcium influx and release, generation of free radicals, and triggering of apoptosis [6, 7].

Inducing hypothermia before cardiac arrest protects the brain from HIBI; deep hypothermia (body core temperature < 20 °C) enables up to 30–40 min of full circulatory arrest without neurological injury [8] and it has been

*Correspondence: claudio.sandroni@policlinicogemelli.it

¹ Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

used since 1955 in cardiac surgery with circulatory arrest [9]. Accidental hypothermia preceding cardiac arrest also confers neuroprotection. In a systematic review that included 210 cases of cardiac arrest related to accidental hypothermia, 153 (73%) survived to hospital discharge. Favorable neurological outcome was reported in 103/105 (89%) survivors. The average body temperature of these patients was 23.9 ± 2.7 °C. Full neurological recovery has been reported in cardiac arrest from accidental hypothermia with body temperatures as low as 13.7 °C after prolonged resuscitation [10].

The potential neuroprotective effects of hypothermia induced after the return of spontaneous circulation (ROSC) from cardiac arrest have been investigated more recently. A systematic review and meta-analysis of experimental evidence included 45 studies published between 1991 and 2019. In these studies, the target temperature ranged from 32 to 36.2 °C in the treatment group and from 36.5 to 39.3 °C in the control group. Notably, the temperatures in the control group were maintained within the normal range for each species used in the model. Results showed that hypothermia reduced mortality by 67% and improved neurological outcomes. These benefits were greater in large animals compared with small animals. Faster cooling rates, lower target temperatures, and shorter delays to starting cooling were independently associated with an increasing effect size [11].

Clinical trials on targeted temperature management

Two pilot trials published in 1997 and 2000 showed the feasibility of cooling post-cardiac arrest patients in the emergency department [12, 13]. In 2002, two clinical trials, one randomized [14] and one pseudorandomized [15], documented improved outcomes with mild hypothermia in patients initially comatose after OHCA with an initial shockable rhythm. In their randomized clinical trial [14], the Hypothermia After Cardiac Arrest (HACA) Study Group reported a higher rate of favorable functional outcome (Cerebral Performance Category [CPC] 1–2) at 6 months with mild hypothermia (32 °C–34 °C) for 24 h compared with normothermia (hypothermia 75/136 [55%] versus normothermia 54/137 [39%]; risk ratio [RR] 1.40; 95% confidence interval [95%CI] 1.08 to 1.81) [14]. The smaller trial documented a higher rate of discharge to home or to a rehabilitation facility after treatment with hypothermia (33 °C) for 12 h compared with normothermia (hypothermia 21/ 43 [(49%) versus normothermia 9/34 [26%]; $p=0.046$)[15]. The ILCOR ALS Task Force considered these studies and the supporting data from animal studies [16] and published an advisory statement in 2003 recommending that unconscious adult OHCA patients with spontaneous circulation should be cooled for 32–34 °C for 12–24 h when

the initial rhythm was ventricular fibrillation (VF) [17]. The Task Force also stated that “such cooling may also be beneficial for other rhythms or in-hospital cardiac arrest.” Some individuals have highlighted significant limitations that placed these early trials at high-risk of bias [18]. The treating clinicians could not be blinded and in the absence of a strict prognostication protocol, decisions on withdrawal of life-sustaining treatment (WLST) and its timing could have been influenced by the use of mild hypothermia. Use of mild-induced hypothermia is likely to require a longer period of sedation, which may delay WLST decisions, giving patients a greater opportunity to awaken.

To address the potential limitations of the two 2002 clinical trials, the Targeted Temperature Management (TTM) trial investigators randomized 950 unconscious adults after OHCA from cardiac cause and any initial rhythm to temperature control at 33 °C compared with a target of 36 °C for 24 h, followed by slow rewarming at 0.5 °C/h [19]. There was no difference in all-cause mortality (the primary outcome) or 6-month functional outcome. Following this trial, many clinicians aimed for a target temperature of 36 °C in post-cardiac arrest patients, while others continued to aim for 33 °C. Some clinicians abandoned the use of temperature control completely [20]. Analyses of large ICU registries in Australia and New Zealand [21, 22] and in the United Kingdom [23] documented an increase in the lowest temperature of post-cardiac arrest patients in the first 24 h in ICU since publication of the TTM trial. This was associated with an increase in the frequency of fever in the first 24 h. The lowest temperature in the first 24 h was evaluated because this is collected routinely for sickness severity scoring and case mix adjustment. Although the unadjusted mortality rate was higher in the post-TTM period, analyses that removed all temperature-affected variables showed no difference in the adjusted mortality rate between pre- and post-TTM periods. If any of the components of a risk-adjustment model are affected by a treatment intervention—in this case temperature—it invalidates the risk calculation. In these studies, the changes in risk-adjusted mortality mirrored the changes in temperature. It is possible that the decreasing temperatures before publication of the TTM trial were interpreted by the risk models as increasing risk of death and the increasing temperature after publication of the TTM trial interpreted as a decrease in risk of death.

There are several potential reasons for the conflicting results between the two clinical trials in 2002 and the TTM trial of 2013. Unlike the 2002 studies, the TTM trial investigators used a protocolized approach to prognostication: for patients who remained unconscious, a clinician blinded to the group allocation performed a

neurological examination 72 h after the end of the intervention and made a recommendation for continuation or WLST. Temperature was not well controlled or not controlled at all in “normothermia” groups of the 2002 trials, and many of these patients developed fever. Post-cardiac arrest fever is associated with a worse outcome [24–26], but whether this causes the worse outcome is uncertain.

In the TTM-2 study, 1900 adults comatose after resuscitation from all-rhythm OHCA of presumed cardiac or unknown cause were randomized to temperature control at 33 °C or normothermia with early treatment of fever (≥ 37.7 °C) followed by temperature control at 37.5 °C [27]. After the intervention period of 40 h, normothermia was maintained until 72 h after randomization in patients who remained sedated or comatose. The primary outcome, 6-month mortality, was no different between the groups (50% in the hypothermia group and 48% in the normothermia group (RR 1.04; 95% CI 0.94 to 1.14; $p=0.37$). Functional outcome at six months was also the same—55% in both groups had moderately severe disability or worse (modified Rankin scale score ≥ 4 ; RR 1.00; 95% CI 0.92 to 1.09). Arrhythmia resulting in hemodynamic compromise was more common in the hypothermia group than in the normothermia group (24% versus 17%, $p<0.001$). There was no difference in outcome among several prespecified groups, including time to ROSC (greater or less than 25 min) and initial rhythm.

The TTM investigators have undertaken an individual patient data meta-analysis of the TTM-1 and TTM-2 studies [28]. Patients in the 36 °C group from TTM-1 were combined with those in the normothermia group in TTM-2 and were compared with the patients from the 33 °C groups in both TTM studies. The primary outcome, all-cause mortality at 6 months, occurred in 691 of 1398 participants (49.4%) in the 33 °C group and 666 of 1391 participants (47.9%) in the normothermia group (RR 1.03; 95% CI 0.96 to 1.11; $p=0.41$). There was no difference in outcomes between several prespecified subgroups, including initial rhythm and time to ROSC (greater or less than 25 min).

Recent systematic reviews

After the publication of the TTM-2 trial, the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR) commissioned a new systematic review and meta-analysis of trials on temperature management in adult patients with HIBI after resuscitation from OHCA or IHCA from all rhythms [29]. The questions addressed by the systematic review were: (1) temperature control at 32–34 °C compared with normothermia/ fever prevention; (2) the specific target of temperature control; (3) the timing of temperature control initiation; (4) the

method used for temperature control; (5) the duration of temperature control and (6) the rewarming rate from hypothermia. The authors of the systematic review used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to assess the certainty of evidence [30]. This was categorized as very low, low, moderate, or high based on risk of bias, imprecision, indirectness, inconsistency, and publication bias [9].

The review included 38 studies representing 32 trials published between 2001 and 2021. Of these, nine trials compared temperature control with a target of 32–34 °C with normothermia, and six were included in the meta-analyses. Temperature control with a target of 32–34 °C did not result in an improvement in survival (RR 1.08; 95% CI 0.89 to 1.30) or favorable functional outcome (RR 1.21; 95% CI 0.91 to 1.61) at 90 to 180 days after resuscitation. There was substantial heterogeneity across the trials, and the certainty of the evidence was low. Three trials assessed different hypothermic temperature targets and found no difference in outcomes between 33 and 36 °C [19] or between 32, 33, and 34 °C (low certainty of evidence). Ten trials comparing prehospital cooling with no prehospital cooling showed no difference in survival (RR 1.01, 95% CI 0.92 to 1.11) or favorable functional outcome at discharge (RR 1.00, 95% CI 0.90 to 1.11) (moderate certainty of evidence). Three trials comparing endovascular with surface cooling showed no difference in survival or neurological outcome to discharge [31–33]. No trials on rewarming strategies were found.

In the same year (2021), a systematic review and network meta-analysis investigated the efficacy and safety of maintaining different temperature targets after cardiac arrest [34]. The review was restricted to OHCA patients and assessed ten trials (total 4218 patients), including the CAPITAL-CHILL trial on hypothermia at 31 °C versus 34 °C, which was not included in the previous review [35]. Its results confirmed that hypothermia at 31–32 °C, 33–34 °C, and 35–36 °C did not improve survival with good functional outcome as compared to normothermia at 37–37.8 °C (odds ratio [OR] 1.30, [0.73 – 2.30], 1.34 [0.92–1.94], and 1.44[0.74–2.80], respectively). The review also assessed the incidence of adverse events for different temperature targets. The incidence of arrhythmias was higher among patients treated with hypothermia at 31–32 °C and 33–34 °C compared with normothermia, with higher odds observed for lower hypothermic temperature targets (OR 3.58 [1.77–7.26] and 1.45 [1.08–1.94], respectively). The incidence of bleeding and pneumonia was not significantly different.

ILCOR and ERC/ESICM recommendations

Based on the results of the ILCOR-commissioned systematic review, the ILCOR ALS Task Force posted online its recommendations (Table 1) [36, 37].

The most significant change compared with previous recommendations was that hypothermia was no longer recommended for the treatment of comatose cardiac arrest survivors. Instead, the Task Force suggested actively preventing fever (defined as a temperature >37.7 °C) for at least 72 h after ROSC. This recommendation was because, although no difference in neurological outcome was found between patients treated with hypothermia and normothermia or fever prevention, fever prevention probably has fewer side effects and requires fewer resources than hypothermia. In the TTM-2 trial, significantly more patients in the hypothermia group had arrhythmia causing hemodynamic compromise than in the normothermia group (24% vs. 17%, *p* < 0.001). Moreover, in that trial, the majority (54%) of patients in the normothermia group did not require cooling with a device compared with 5% in the hypothermia group [27]. In those patients, the temperature target was maintained using pharmacological measures (acetaminophen), uncovering the body, or lowering ambient temperature.

The ALS ILCOR task force suggested using the term “temperature control” rather than the commonly used term “TTM” to avoid confusion with the TTM-2 randomized controlled trials and preferred using the term “prevention of fever” rather than normothermia. To

provide additional clarity for interpreting future clinical trials and evidence reviews, the Task Force proposed and updated terminology for temperature control strategies (Table 2).

In 2022, the European Resuscitation Council (ERC) and the European Society of Intensive Care Medicine (ESICM) published updated guidelines on temperature control after cardiac arrest [37, 38]. Consistent with the ILCOR consensus document, these guidelines recommend continuous monitoring of core temperature and actively preventing fever for at least 72 h in patients who remain comatose after cardiac arrest.

Points for discussion and knowledge gaps

Despite insufficient evidence to recommend for or against temperature control at 32–36.8 °C after cardiac arrest, most members of the ILCOR ALS Task Force and the ERC-ESICM panel were keen to leave open this option in some patient categories according to local protocols. One reason was that most patients included in the evidence reviews had been in cardiac arrest with an initial shockable cardiac rhythm and a primary cardiac cause [19, 27, 39]. Other categories of patients in whom temperature control with hypothermia could be more effective may exist. However, these populations have not been identified with certainty. In the HYPERION trial, conducted on 584 patients resuscitated from non-shockable cardiac arrest (27% in-hospital), the rates of 90-day survival with favorable functional outcome were significantly higher

Table 1 ILCOR Recommendations on temperature control after cardiac arrest. From [36]

We suggest actively preventing fever by targeting a temperature of 37.5 °C or less for patients who remain comatose after ROSC from cardiac arrest (weak recommendation, low certainty of evidence)

- Whether subpopulations of cardiac arrest patients may benefit from targeting hypothermia at 32–34 °C remains uncertain
- Comatose patients with mild hypothermia after ROSC should not be actively warmed to achieve normothermia (good practice statement)
- We recommend against the routine use of prehospital cooling with rapid infusion of large volumes of cold IV fluid immediately after ROSC (strong recommendation, moderate certainty of evidence)
- We suggest surface or endovascular temperature control techniques when temperature control is used in comatose patients after ROSC (weak recommendation, low certainty of evidence)
- When a cooling device is used, we suggest using a temperature control device that includes a feedback system based on continuous temperature monitoring to maintain the target temperature (good practice statement)
- We suggest active prevention of fever for at least 72 h in post-cardiac arrest patients who remain comatose (good practice statement)

Table 2 Proposed ILCOR terminology for temperature control interventions

Hypothermic Temperature Control	Active temperature control with the target temperature below the normal range
Normothermic Temperature Control	Active temperature control with the target temperature in the normal range
Fever Prevention Temperature Control	Monitoring temperature and actively preventing and treating temperature above the normal range
No Temperature Control	No protocolized active temperature control strategy

after 24-h temperature control targeted at 33 °C versus 37 °C (10.2 vs. 5.7%; $p=0.04$) [40]. Notably, the HYPERION study had a fragility index of 1, meaning that switching only one patient in the treatment group from good to poor neurological outcome at 90 days would convert the statistically significant difference between groups observed in the study to non-significant. Data from the TTM and the TTM-2 trials showed no benefit from controlled temperature targeted at hypothermia in patients with non-shockable rhythm. An ancillary analysis of the HYPERION trial showed larger differences in favor of temperature control targeted at 33 °C in the subpopulation of patients with in-hospital arrest (16.4% vs. 5.8%; $p=0.03$) [41]. However, mortality did not differ between the two groups. A recent multicenter trial [42] conducted on 249 patients resuscitated from in-hospital cardiac arrest in Germany showed no benefit of temperature control targeted at 32–34 °C on mortality at six months compared with normothermia.

The presence of confounders, such as a different etiology or comorbidities, may limit the reliability of the first recorded rhythm (shockable vs. non-shockable) as a marker of the severity of HIBI. A better approach could be to investigate the effectiveness of temperature control dose—in terms of target temperature and duration—based on prognostic scores such as the cardiac arrest hospital prognosis (CAHP) score [43] or on direct clinical indices of HIBI severity, such as those currently used as prognostic tests in post-cardiac arrest coma [44, 45]. “Prognostic enrichment” has been advocated to focus randomized trials on patients more likely to benefit from the assessed treatment [46].

A possible reason for the lack of consistent benefit from hypothermia after cardiac arrest is that in the studies conducted so far, the target temperature was reached several hours after ROSC and potentially outside the therapeutic window. In the 45 animal studies that showed a consistent benefit from temperature control targeted at hypothermia after cardiac arrest, hypothermia was induced in 1 h or less after ROSC, and the mean cooling rate was 11 °C/h (range 0.8 °C/h to 27 °C/h) [11]. This cooling rate has never been achieved in any clinical study. In one randomized trial [47], prehospital administration of up to 2 L of 4 °C normal saline after ROSC followed by hospital cooling reduced the time to achieving the target temperature of 34 °C by more than one hour (from 4.2[3.8–4.6] to 3.0[2.6–3.4] hours). However, there was no difference between groups in terms of survival or neurological outcome at discharge. Moreover, the intervention was associated with significantly higher rates of rearrest in the field and pulmonary edema on the first chest X-ray. The 2021 ERC-ESICM Guidelines

recommend against the routine use of prehospital cooling with rapid infusion of large volumes of cold IV fluid immediately after ROSC (Table 1).

Two clinical studies [48, 49] showed that intranasal cooling during resuscitation from OHCA achieved significantly shorter times to both tympanic and core target temperature compared with no intranasal cooling, and it was not associated with higher rates of adverse events. Neurological outcome was not different between the study groups. An individual patient data meta-analysis based on these two studies showed that intranasal cooling was associated with increased rates of favorable neurological outcome (34.2% vs. 24.0%; RR 1.43 [95% CI 1.01–2.02]) in patients with initial shockable rhythms [50].

The optimal duration of temperature control after cardiac arrest is still a matter of debate. The ILCOR review included only one trial [39], which showed no difference in outcomes between temperature control at 32–34 °C for 24 h compared with 48 h after OHCA. The ongoing multicenter ICECAP study (NCT 04,217,551) in the United States (US) is investigating the effects of different durations [from 6 to 72 h] of controlled temperature targeted at 33 °C on neurological outcome at three months. The 2021 recommendations suggest preventing fever for at least 72 h after ROSC, based on the two TTM trials [19, 27] where the temperature was controlled for at least 72 h in patients who remained sedated or comatose.

There is no universally accepted definition of normothermia. In 2017, a large study based on 243,506 measurements made in a cohort of 35,488 non-infectious adult outpatients in a single academic hospital in the USA showed that the 95% range for body temperature was 35.7 to 37.3 °C, and the 99% range was 35.3 to 37.7 °C [51]. The site of temperature measurements was oral in most patients (88%). Patients assessed in the emergency department were excluded from the study. Whether these ranges can be generalized to core temperatures measured in comatose resuscitated patients is uncertain.

A final knowledge gap concerns the neuroprotective role of normothermia. Although hyperthermia is considered to be detrimental after cardiac arrest, there are no trials comparing normothermia or fever prevention with no temperature control in patients who are comatose after cardiac arrest.

Conclusions

Twenty years after the publication of the first randomized trials on hypothermia after cardiac arrest, the protective role of temperature control for HIBI is still debated. Given the lack of any consistent evidence in favor of hypothermic temperature control, current

guidelines recommend continuous monitoring of core temperature and actively preventing fever (>37.7 °C) in adult patients who are comatose after resuscitation from cardiac arrest, regardless of cardiac arrest location or initial rhythm. However, the overall certainty of evidence regarding temperature control after cardiac arrest is low. Future studies are warranted to identify patient populations for whom hypothermic temperature control could be beneficial and if normothermia or fever prevention has a neuroprotective effect compared with no temperature control.

Abbreviations

ALS: Advanced life support; CAHP: Cardiac Arrest Hospital Prognosis Score; CPC: Cerebral performance category; HACA: Hypothermia after cardiac arrest; HIBI: Hypoxic-ischemic brain injury; IHCA: In-hospital cardiac arrest; ILCOR: International Liaison Committee on Resuscitation; OHCA: Out-of-hospital cardiac arrest; ROSC: Return of spontaneous circulation; TTM: Targeted temperature management; VF: Ventricular fibrillation; WLST: Withdrawal of life-sustaining treatment.

Acknowledgements

None

Authors' contributions

C.S. and J.N. designed the review. DN performed the literature search. All authors collaborated in manuscript drafting. C.S. prepared the tables. All the authors reviewed the final draft of the manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not Applicable.

Declarations

Ethics approval and consent to participate

Not Applicable.

Consent for publication

Not Applicable.

Competing interests

Daniele Natalini. Editorial board member, BMC Anesthesiology. No financial competing interests. Claudio Sandroni. Associate editor, Intensive Care Medicine; Editorial board member, Resuscitation. No financial competing interests. Jerry P. Nolan. The author receives payment from Elsevier (Editor-in-Chief). Editor-in-Chief, Resuscitation; Board member, European Resuscitation Council.

Author details

¹Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy. ²Department of Intensive Care, Emergency Medicine, and Anesthesiology, Fondazione Policlinico Universitario A. Gemelli, IRCCS. Largo A. Gemelli 8, 00168 Rome, Italy. ³Warwick Clinical Trials Unit, Warwick Medical School, Warwick University, Gibbet Hill, Coventry CV4 7AL, UK. ⁴Department of Anaesthesia and Intensive Care Medicine, Royal United Hospital, Bath BA1 3NG, UK. ⁵Department of Anesthesiology and Intensive Care Medicine, Catholic University of The Sacred Heart, Fondazione 'Policlinico Universitario A. Gemelli' IRCCS. L.go F. Vito 1, 00168 Rome, Italy.

Received: 3 November 2022 Accepted: 12 November 2022

Published online: 24 November 2022

References

1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American heart association. *Circulation*. 2022;145:e153–639.
2. Australia and New Zealand Cardiac Arrest Outcome and Determinants of ECMO (ANZ-CODE) Investigators. The epidemiology of in-hospital cardiac arrests in Australia: a prospective multicentre observational study. *Crit Care Resusc*. 2019;21:180–7.
3. Sandroni C, Nolan J, Cavallaro F, Antonelli M. In-hospital cardiac arrest: incidence, prognosis and possible measures to improve survival. *Intensive Care Med*. 2007;33:237–45.
4. Lemiale V, Dumas F, Mongardon N, Giovanetti O, Charpentier J, Chiche JD, et al. Intensive care unit mortality after cardiac arrest: the relative contribution of shock and brain injury in a large cohort. *Intensive Care Med*. 2013;39:1972–80.
5. Witten L, Gardner R, Holmberg MJ, Wiberg S, Moskowitz A, Mehta S, et al. Reasons for death in patients successfully resuscitated from out-of-hospital and in-hospital cardiac arrest. *Resuscitation*. 2019;136:93–9.
6. Sandroni C, Cronberg T, Sekhon M. Brain injury after cardiac arrest: pathophysiology, treatment, and prognosis. *Intensive Care Med*. 2021;47:1393–414.
7. Perkins GD, Callaway CW, Haywood K, Neumar RW, Lilja G, Rowland MJ, et al. Brain injury after cardiac arrest. *Lancet*. 2021;398:1269–78.
8. Gocoł R, Hudziak D, Bis J, Mendrala K, Morkisz Ł, Podsiadło P, et al. The role of deep hypothermia in cardiac surgery. *Int J Environ Res Public Health*. 2021. <https://doi.org/10.3390/ijerph18137061>.
9. Lewis FJ, Tauric M, Varco RL, Nuazi S. The surgical anatomy of atrial septal defects: experiences with repair under direct vision. *Ann Surg*. 1955;142:401–17.
10. Gilbert M, Busund R, Skagseth A, Nilsen PA, Solbø JP. Resuscitation from accidental hypothermia of 13-7°C with circulatory arrest. *Lancet*. 2000;355(9201):375–6. [https://doi.org/10.1016/S0140-6736\(00\)01021-7](https://doi.org/10.1016/S0140-6736(00)01021-7).
11. Arrich J, Herkner H, Mullner D, Behringer W. Targeted temperature management after cardiac arrest. A systematic review and meta-analysis of animal studies. *Resuscitation*. 2021;162:47–55.
12. Bernard SA, Jones BM, Horne MK. Clinical trial of induced hypothermia in comatose survivors of out-of-hospital cardiac arrest. *Ann Emerg Med*. 1997;30:146–53.
13. Zeiner A, Holzer M, Sterz F, Behringer W, Schorkhuber W, Mullner M, et al. Mild resuscitative hypothermia to improve neurological outcome after cardiac arrest. A clinical feasibility trial. *Hypothermia After cardiac arrest (HACA) study group. Stroke*. 2000;31:86–94.
14. Hypothermia after Cardiac Arrest Study G. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *New Engl J Med*. 2002;346:549–56.
15. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med*. 2002;346:557–63.
16. Sterz F, Safar P, Tisherman S, Radovsky A, Kuboyama K, Oku K. Mild hypothermic cardiopulmonary resuscitation improves outcome after prolonged cardiac arrest in dogs. *Crit Care Med*. 1991;19:379–89.
17. Nolan JP, Morley PT, Vanden Hoek TL, Hickey RW, Kloeck WG, Billi J, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the international liaison committee on resuscitation. *Circulation*. 2003;108:118–21.
18. Nielsen N, Friberg H, Gluud C, Herlitz J, Wetterslev J. Hypothermia after cardiac arrest should be further evaluated—a systematic review of randomised trials with meta-analysis and trial sequential analysis. *Int J Cardiol*. 2011;151:333–41.
19. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. *N Engl J Med*. 2013;369:2197–206.
20. Bradley SM, Liu W, McNally B, Vellano K, Henry TD, Mooney MR, et al. Temporal trends in the use of therapeutic hypothermia for out-of-hospital cardiac arrest. *JAMA Netw Open*. 2018;1:e184511.
21. Salter R, Bailey M, Bellomo R, Eastwood G, Goodwin A, Nielsen N, et al. Changes in temperature management of cardiac arrest patients following publication of the target temperature management trial. *Crit Care Med*. 2018;46:1722–30.

22. Young PJ, Bailey M, Bellomo R. An update on temperature management following cardiac arrest in Australian and New Zealand ICUs. *Crit Care Med.* 2021;49:e1040–2.
23. Nolan JP, Orzechowska I, Harrison DA, Soar J, Perkins GD, Shankar-Hari M. Changes in temperature management and outcome after out-of-hospital cardiac arrest in United Kingdom intensive care units following publication of the targeted temperature management trial. *Resuscitation.* 2021;162:304–11.
24. Zeiner A, Holzer M, Sterz F, Schörkhuber W, Eisenburger P, Havel C, et al. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. *Arch Intern Med.* 2001;161:2007–12.
25. Leary M, Grossstreuer AV, Iannacone S, Gonzalez M, Shofar FS, Povey C, et al. Pyrexia and neurologic outcomes after therapeutic hypothermia for cardiac arrest. *Resuscitation.* 2013;84:1056–61.
26. Bro-Jeppesen J, Hassager C, Wanscher M, Sørensen H, Thomsen JH, Lippert FK, et al. Post-hypothermia fever is associated with increased mortality after out-of-hospital cardiac arrest. *Resuscitation.* 2013;84:1734–40.
27. Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. *N Engl J Med.* 2021;384:2283–94.
28. Holgersson J, Meyer MAS, Dankiewicz J, Lilja G, Ullén S, Hassager C, et al. Hypothermic versus normothermic temperature control after cardiac arrest. *NEJM Evid.* 2022;1.
29. Granfeldt A, Holmberg MJ, Nolan JP, Soar J, Andersen LW. Targeted temperature management in adult cardiac arrest: Systematic review and meta-analysis. *Resuscitation.* 2021;167:160–72.
30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008;336:924–6.
31. Pittl U, Schratzer A, Desch S, Diosteanu R, Lehmann D, Demmin K, et al. Invasive versus non-invasive cooling after in- and out-of-hospital cardiac arrest: a randomized trial. *Clin Res Cardiol.* 2013;102:607–14.
32. Deye N, Cariou A, Girardie P, Pichon N, Megarbane B, Midez P, et al. Endovascular versus external targeted temperature management for patients with out-of-hospital cardiac arrest: a randomized. *Controll Study Circ.* 2015;132:182–93.
33. Look X, Li H, Ng M, Lim ETS, Pothiwala S, Tan KBK, et al. Randomized controlled trial of internal and external targeted temperature management methods in post- cardiac arrest patients. *Am J Emerg Med.* 2018;36:66–72.
34. Fernando SM, Di Santo P, Sadeghirad B, Lascarrou JB, Rochweg B, Mathew R, et al. Targeted temperature management following out-of-hospital cardiac arrest: a systematic review and network meta-analysis of temperature targets. *Intensive Care Med.* 2021;47:1078–88.
35. Le May M, Osborne C, Russo J, So D, Chong AY, Dick A, et al. Effect of moderate vs mild therapeutic hypothermia on mortality and neurologic outcomes in comatose survivors of out-of-hospital cardiac arrest: the CAPITAL CHILL randomized clinical trial. *JAMA J Am Med Assoc.* 2021;326:1494–503.
36. Soar J, Nolan JP, Andersen LW, Böttiger BW, Coupe rK, Deakin CD, et al. Temperature management in adult cardiac arrest consensus on science with treatment recommendations Brussels, Belgium: International Liaison Committee on Resuscitation (ILCOR) Advanced Life Support Task Force. 2021. Available from: [http://ilcor.org.Last](http://ilcor.org>Last). Accessed 15 July 2022.
37. Sandroni C, Nolan JP, Andersen LW, Bottiger BW, Cariou A, Cronberg T, et al. ERC-ESICM guidelines on temperature control after cardiac arrest in adults. *Intensive Care Med.* 2022;48:261–9.
38. Nolan JP, Sandroni C, Andersen LW, Böttiger BW, Cariou A, Cronberg T, et al. ERC-ESICM guidelines on temperature control after cardiac arrest in adults. *Resuscitation.* 2022;172:229–36.
39. Kirkegaard H, Søreide E, de Haas I, Pettilä V, Taccone FS, Arus U, et al. Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital cardiac arrest: a randomized clinical trial. *JAMA J Am Med Assoc.* 2017;318:341–50.
40. Lascarrou JB, Merdji H, Le Gouge A, Colin G, Grillet G, Girardie P, et al. Targeted temperature management for cardiac arrest with nonshockable rhythm. *N Engl J Med.* 2019;381:2327–37.
41. Blanc A, Colin G, Cariou A, Merdji H, Grillet G, Girardie P, et al. Targeted temperature management after in-hospital cardiac arrest: an ancillary analysis of targeted temperature management for cardiac arrest with nonshockable rhythm trial data. *Chest.* 2022;162:356–66.
42. Wolfrum S, Roedel K, Hanebutte A, Pfeifer R, Kurowski V, Riessen R, et al. Temperature control after in-hospital cardiac arrest: a randomized clinical trial. *Circulation.* 2022. <https://doi.org/10.1161/CIRCULATIONAHA.122.060106>.
43. Maupain C, Bougouin W, Lamhaut L, Deye N, Diehl JL, Geri G, et al. The CAHP (Cardiac Arrest Hospital Prognosis) score: a tool for risk stratification after out-of-hospital cardiac arrest. *Eur Heart J.* 2016;37:3222–8.
44. Sandroni C, D'Arrigo S, Cacciola S, Hoedemaekers CWE, Kamps MJA, Oddo M, et al. Prediction of poor neurological outcome in comatose survivors of cardiac arrest: a systematic review. *Intensive Care Med.* 2020;46:1803–51.
45. Sandroni C, D'Arrigo S, Cacciola S, Hoedemaekers CWE, Westhall E, Kamps MJA, et al. Prediction of good neurological outcome in comatose survivors of cardiac arrest: a systematic review. *Intensive Care Med.* 2022;48:389–413.
46. Viele K, Girard TD. Risk, results, and costs: optimizing clinical trial efficiency through prognostic enrichment. *Am J Respir Crit Care Med.* 2021;203:671–2.
47. Kim F, Nichol G, Maynard C, Hallstrom A, Kudenchuk PJ, Rea T, et al. Effect of prehospital induction of mild hypothermia on survival and neurological status among adults with cardiac arrest: a randomized clinical trial. *JAMA J Am Med Assoc.* 2014;311:45–52.
48. Castrén M, Nordberg P, Svensson L, Taccone F, Vincent JL, Desruelles D, et al. Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness). *Circulation.* 2010;122:729–36.
49. Nordberg P, Taccone FS, Truhlar A, Forsberg S, Hollenberg J, Jonsson M, et al. Effect of trans-nasal evaporative intra-arrest cooling on functional neurologic outcome in out-of-hospital cardiac arrest: the PRINCESS randomized clinical trial. *JAMA.* 2019;321:1677–85.
50. Taccone FS, Hollenberg J, Forsberg S, Truhlar A, Jonsson M, Annoni F, et al. Effect of intra-arrest trans-nasal evaporative cooling in out-of-hospital cardiac arrest: a pooled individual participant data analysis. *Crit Care.* 2021;25:198.
51. Obermeyer Z, Samra JK, Mullainathan S. Individual differences in normal body temperature: longitudinal big data analysis of patient records. *BMJ.* 2017;359:j5468.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

